No Data
Shanghai Henlius Biotech Advances Phase 3 Trial for Cancer Treatment
HENLIUS (02696.HK): The international multicenter phase 3 clinical trial application comparing HLX22 (recombinant humanized anti-HER2 monoclonal antibody injection) combined with trastuzumab and chemotherapy (XELOX) to trastuzumab and chemotherapy (XELOX)
Gelonghui, April 28 - HENLIUS (02696.HK) announced that recently, the international multi-center phase III clinical trial application for HLX22 (recombinant humanized anti-HER2 monoclonal antibody injection) combined with trastuzumab and chemotherapy (XELOX) compared to trastuzumab and chemotherapy (XELOX) combined or not combined with pembrolizumab for the first-line treatment of HER2-positive locally advanced or metastatic gastroesophageal junction and gastric cancer has been approved in Germany. The company plans to conduct clinical trials in Germany and other EU countries once conditions are met. HLX22 is licensed by the company and later self-researched.
Express News | Shanghai Henlius Biotech Inc - Application for International Multi-Center- Phase 3 Clinical Trial of Hlx22, Others, Approved in Germany
Henlius Biotech Licenses Lung Cancer Drug Hansizhuang for Commercialization in South Korea
Express News | Shanghai Henlius Biotech - Enters License Agreement With Alvogen Korea
[Popular Industry] The Global competition accelerates as China's Innovative Drugs Industry enters a new cycle.
King Wu Finance | The Global Innovative Drugs research and development landscape is undergoing profound changes. The latest assessment by McKinsey shows that the USA dominates the leading tier of global drug development, accounting for over half of the world's new drug research, while China's new drug development has entered the forefront of the global second tier. In the most advanced fields of stem cell therapy and gene therapy, the number of clinical studies being conducted puts China and the USA in the top two positions globally. The equal number of clinical studies between China and the USA marks the transition of Chinese innovative drugs from "catching up" to "keeping pace with" and even "leading". In this process, the frequent clinical achievements of domestic enterprises and enhanced policy support are propelling the Industry into a rapid development phase.
